Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P41252

UPID:
SYIC_HUMAN

ALTERNATIVE NAMES:
Isoleucyl-tRNA synthetase

ALTERNATIVE UPACC:
P41252; A8KAE9; Q5TCD0; Q7Z3T4; Q9H588

BACKGROUND:
The enzyme Isoleucine--tRNA ligase, cytoplasmic, alternatively known as Isoleucyl-tRNA synthetase, is essential for the synthesis of proteins. It specifically attaches isoleucine to its tRNA, a critical step in translating the genetic code into proteins. This precision is crucial for maintaining the integrity of protein synthesis, impacting cellular health and organismal development.

THERAPEUTIC SIGNIFICANCE:
Linked to a severe autosomal recessive disorder characterized by growth retardation and intellectual disability, Isoleucine--tRNA ligase's dysfunction highlights its importance. Exploring the enzyme's role could unveil novel therapeutic avenues, potentially transforming treatment paradigms for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.